Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 1, 2011, Pages

  Wetmore, James B ^a   Santos, Peter W ^a   Mahnken, Jonathan D ^a   Krebill, Ron ^a   Menard, Rochelle ^a   Gutta, Hema ^a   Quarles, L Darryl ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CALCIUM SENSING RECEPTOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DIALYSATE; FEMALE; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; KIDNEY FAILURE; MALE; METABOLIC PARAMETERS; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PARATHYROID FUNCTION; PARATHYROID HORMONE RELEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

EID: 78650871573     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1277     Document Type: Article

References (30)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK 1998 Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617
2. Yamashita T, Yoshioka M, Itoh N 2000 Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494-498
3. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N 2002 Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265-28270
4. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435
5. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y 2004 FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65:1943-1946
6. Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M 2005 Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67:1120-1125
7. Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T 2005 Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 9:336-339
8. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M 2005 Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67:1171-1178 (Pubitemid 41623344)
9. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD 2003 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419-37426
10. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD 2006 Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305-1315
11. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N 2003 Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1α,25-dihydroxyvitamin D3 production. J Biol Chem 278:2206-2211
12. Perwad F, Zhang MY, Tenenhouse HS, Portale AA 2007 Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1α-hydroxylase expression in vitro. Am J Physiol Renal Physiol 293:F1577-F1583
13. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M 2008 Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584-592
14. Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, Westin G, Larsson TE 2007 Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125-131
15. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J 2007 The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008
16. Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M 2004 Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44:481-487 (Pubitemid 39164625)
17. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M 2005 Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 101:c94-c99 (Pubitemid 41208897)
18. Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prié D 2008 Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 73:102-107
19. Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, Munoz-Castaneda JR, Shalhoub V, Almaden Y, Rodriguez M 2010 FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 21:1125-1135
20. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T 2010 Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77:211-218
21. Indridason OS, Heath 3rd H, Khosla S, Yohay DA, Quarles LD 1996 Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int 50:1663-1671
22. McCullough CE, Searle SR 2001 Generalized, linear, and mixed models. Chap 6. New York: John Wiley, Sons
23. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O 2006 SAS for mixed models. 2nd ed. Chap 8. Cary, NC: SAS Institute, Inc.
24. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692
25. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774
26. Nabel EG, Yang ZY, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ 1993 Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 362:844-846
27. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D 2009 Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150:4835-4845
28. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P, Dartevelle P, Simonneau G, Adnot S, Maitre B, Raffestin B, Eddahibi S 2009 Endothelial-derived FGF 2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 119:512-523
29. Burnett SM, Gunawardene SC, Bringhurst FR, Jüppner H, Lee H, Finkelstein JS 2006 Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21:1187-1196
30. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD 2010 Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 21:353-361